Lansoprazole

Major

Lansoprazole Neratinib Nerlynx Decreased neratinib solubility, absorption, and exposure Details Lansoprazole Nilotinib Reduced nilotinib exposure and reduced efficacy of nilotinib Details Lansoprazole Nirogacestat Ogsiveo Reduced nirogacestat/CYP2C19 substrate exposure and reduced efficacy of nirogacestat/CYP2C19 substrate Details Lansoprazole Nivolumab Opdivo Reduced efficacy of nivolumab Details Lansoprazole Octreotide Bynfezia Decreased octreotide bioavailability Details Lansoprazole Palbociclib Ibrance Reduced efficacy of palbociclib Details Lansoprazole Paltusotine Palsonify Reduced paltusotine exposure and reduced efficacy of paltusotine Details Lansoprazole Pazopanib Votrient Reduction in pazopanib bioavailability Details Lansoprazole Pexidartinib Turalio Reduced pexidartinib exposure Details Lansoprazole Phenobarbital Fidoquel Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Lansoprazole Pirtobrutinib Jaypirca Increased sensitive CYP2C19 substrate exposure and an increased risk of sensitive CYP2C19 substrate-related adverse effects Details Lansoprazole Primidone Mysoline Reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 substrate Details Lansoprazole Rilzabrutinib Wayrilz Reduced rilzabrutinib exposure and reduced efficacy of rilzabrutinib Details Lansoprazole Saquinavir Significant increases in saquinavir exposure Details Lansoprazole Secretin Human Chirhostim False positive secretin stimulation test results Details Lansoprazole Selpercatinib Retevmo Reduced selpercatinib exposure and reduced anti-tumor activity Details Lansoprazole Sotorasib Lumakras Reduced sotorasib exposure and anti-tumor activity Details Lansoprazole Sparsentan Filspari Reduced sparsentan exposure, reduced efficacy of sparsentan, reduced CYP2C19 substrate exposure and reduced efficacy of CYP2C19 su... Details Lansoprazole Sunitinib Sutent Reduction in sunitinib bioavailability Details Lansoprazole Tacrolimus Astagraf Increased tacrolimus concentration and an increased risk of toxicity Details Lansoprazole Taletrectinib Ibtrozi Reduced taletrectinib exposure and reduced efficacy of taletrectinib Details Lansoprazole Velpatasvir Decreased velpatasvir exposure Details Lansoprazole Vismodegib Erivedge Reduced vismodegib systemic exposure Details Lansoprazole Voriconazole Vfend Increased lansoprazole exposure Details Lansoprazole Ziftomenib Komzifti Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Lansoprazole Methotrexate Injection Abitrexate® An increased methotrexate exposure, an increased risk of methotrexate-related severe adverse reactions, reduced active metabolite... Details Lansoprazole Methylphenidate Transdermal Patch Daytrana Altered pharmacodynamic and changes in release profile of methylphenidate Details Lansoprazole Nivolumab Injection Opdivo Reduced efficacy of nivolumab Details Lansoprazole Octreotide Injection Bynfezia Decreased octreotide bioavailability Details